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Abstract: Background and Objectives: A comparative survey of Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (ME/CFS) patients was carried out in three countries, with the aim of identifying
appropriate policy measures designed to alleviate the burden of disease both on patients and their
families, and also on public institutions. The survey addressed demographic features, the economic
impact of the disease on household incomes, patterns of medical and social care, specific therapies,
social relationships, and the impact of the illness on quality of life. Materials and Methods: Parallel
surveys were undertaken in Italy, Latvia, and the UK. There were 88 completed responses from
Italy, 75 from Latvia, and 448 from the UK. To facilitate comparisons, 95% confidence intervals were
calculated in respect of responses to questions from all three countries. To explore to what extent
general practitioners (GPs) manage ME/CFS disease, a separate questionnaire for GPs, with questions
about the criteria for granting a diagnosis, laboratory examinations, the involvement of specialists,
and methods of treatment, was undertaken in Latvia, and there were 91 completed responses from
GPs. Results: The results are presented in respect of sociodemographic information, household
income, disease progression and management, perceived effectiveness of treatment, responsibility
for medical care, personal care, difficulty explaining the illness, and quality of life. Demographic
details were similar in all three countries, and the impact of illness on net household incomes and
quality of life. There were significant differences between the three countries in illness progression
and management, which may reflect differences in patterns of health care and in societal attitudes.
Graded exercise therapy, practiced in the UK, was found to be universally ineffective. Conclusions:
There were similarities between respondents in all three countries in terms of demographic features,
the impact of the illness on household incomes and on quality of life, and on difficulties experienced
by respondents in discussing their illness with doctors, but also differences in patterns of medical
care, availability of social care, and societal attitudes to ME/CFS.
Keywords: Myalgic Encephalomyelitis; chronic fatigue syndrome; ME/CFS; economic impact;
medical care; social care; quality of life
1. Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-
system disorder, with severe, profound incapacitating fatigue not alleviated by rest, and
post-exertional malaise. Other symptoms include cognitive dysfunction, sleep disturbance,
and muscle pain. As a result, marked reductions in functional activity and quality of life
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are encountered [1]. Cases vary markedly in the symptoms they manifest, in severity, and
in disease progression. ME/CFS most frequently occurs between ages 20 and 50 but can
affect all ages. The majority of patients are female [2]. UK experience suggests that there
may be two million patients throughout Europe [3]. Much work has been carried out over
several decades to investigate the nature of the syndrome, but marked uncertainty remains
over its definition, diagnosis, treatment, and economic impact [4].
The problem of determining the economic impact of ME/CFS in Europe was con-
sidered by the socioeconomics working group of EUROMENE (vide infra). The economic
burden is significant, with productivity losses appearing to be the largest cost element,
while effective prevention and treatment give scope for substantial cost reductions. There
are problems of economic evaluation because of the arbitrariness of case definitions, and
doctors who are unable to diagnose the condition, for reasons including disbelief and lack
of understanding, so there is a lack of accurate incidence and prevalence data. Recommen-
dations of the working group include the use of the Fukuda (CDC-1994) case definition
and Canadian Consensus Criteria (CCC), a pan-European common symptom checklist,
implementation of prevalence-based cost-of-illness studies in different countries using
an agreed data list, the use of purchasing power parities (PPP) to facilitate international
comparisons, and the use of EuroQol-5D to measure health status [5].
The European Network on ME/CFS (EUROMENE) is a collaborative, Europe-wide,
consortium aiming to address serious gaps in knowledge of ME/CFS. In 2016, EUROMENE
received funding from the European Union through the COST programme, and was for-
mally constituted as COST Action 15111. This action aims to “promote further research
on ME/CFS with high economic impact” [6]. Working Group 3, on socioeconomics,
has endeavored to appraise the economic implications of the disease, its specific objec-
tives including surveying data from European countries on the economic losses due to
ME/CFS and developing ways to calculate the direct and indirect economic burdens due
to ME/CFS [7].
In pursuit of these objectives, a comparative questionnaire study of ME/CFS patients
was carried out in three countries, Italy, Latvia, and the UK, with the aim of identifying
appropriate policy measures designed to alleviate the burden of disease both on patients
and their families, and on governments. In particular, reducing diagnostic delays should
limit progression to severe, prolonged disease, with consequent reductions in its economic
impact, including direct and indirect costs, and, most importantly, productivity costs.
2. Methods
Parallel surveys were undertaken in Italy, Latvia, and the UK. In Italy, a questionnaire
(Supplementary Material) was distributed to 104 adult patients living in the north of the
country, with the support of the Association of Patients CFS Onlus, which has an important
role in assisting and supporting medical research and in disseminating knowledge of
the disease [8]. The questionnaire had several sections. The first section sought general
information (age, gender, education, place of residence, etc.), the second section addressed
clinical history, and the third focused on the socio-economic consequences of the disease,
including restrictions on daily life, sources of assistance, and understanding and awareness
of the disease. The final section sought information on health status, reliance on physicians,
the possible causes of illness, and future expectations. Quality of life was assessed using
the instrument EuroQol-5D [9–11]. The patients were also asked to rate their quality of life
in a scale from 0 to 100, where 100 represents the best imaginable QoL and 0 the worst,
for the year before onset of illness, and for the year immediately preceding completion of
the survey.
In Latvia, the patients’ questionnaire (Supplementary Material) has been designed
in accordance with the questionnaire prepared by the Italian team of Working Group 3
(socioeconomic), employed in the European program COST Action 15111 EUROMENE, in
order to get a comparable data. The sample has included 75 valid observations, performed
by 62 women and 13 men. Simultaneously, a questionnaire for GPs was distributed with
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support of the Latvian Association of Rural Family Doctors, taking into account that this
association represents GPs working in urban and rural areas. The survey had included
20 questions, mostly on the criteria for granting a diagnosis, laboratory examinations,
the involvement of specialists, and the methods of treatment. There were 91 completed
responses from GPs.
To obtain comparison data from the UK, an internet survey was set up using the
facility ‘Smartsurvey’. A link to the questionnaire was circulated on 19 October 2020 via
the internet group ‘LocalME’, with a request for UK residents with medically diagnosed
ME/CFS to respond by 31 October. 448 questionnaires were completed by the deadline.
The survey was structured in order to replicate as much as possible the Italian original
questionnaire, though some variations were inevitable because of differences in the ways
in which healthcare services are delivered. For the international comparison report we
have calculated 95% confidence intervals for most of the parameters examined.
3. Results
In Italy, 88 questionnaires were correctly completed, and in Latvia, there were 75 valid
responses from patients and 91 completed responses from GPs. There were 448 completed
responses to the UK survey. Comparative results are presented below under the following
headings—sociodemographic information, household income, disease progression and
management, perceived effectiveness of treatment, responsibility for medical care, personal
care, difficulty explaining the illness, and quality of life. The results of the additional GP
survey in Latvia on the management of ME/CFS are provided in the concluding section.
3.1. Sociodemographic Information
The respondents ranged in age from 17 to 81, with an average of 50 years, and there
was no significant difference between the three countries in terms of average age. In
addition, there was no significant difference between the three countries in the gender
distribution of respondents; in all three, a large majority of respondents were female. A very
much higher proportion of UK respondents had post-school educational qualifications than
in Latvia or Italy, but there was no significant difference between the latter two countries in
that respect. Around half of all respondents in the three countries were married. In Latvia,
a third of respondents lived alone. The proportions in Italy and the UK were lower, but
these differences were not statistically significant. The results are detailed in Table 1.
Table 1. Sociodemographic data.








Italy 88 47.0 13.9 44.1–49.4
Latvia 75 50.0 14.7 46.6–53.3
UK 447 42.1 14.0 40.9–43.5
Gender
(No. females)
Italy 88 68 77.3 67.1–87.4
Latvia 75 62 82.7 73.1–92.3




Italy 88 34 38.7 21.9–55.3
Latvia 74 32 43.2 25.7–60.8
UK 374 314 83.9 79.8–88.1
Marital status
(No. married)
Italy 88 39 44.3 28.4–60.2
Latvia 75 45 60.0 45.4–74.6
UK 446 205 46.0 39.0–52.9
No. living alone
Italy 88 17 19.4 0.2–38.5
Latvia 74 25 33.8 14.9–52.7
UK 447 107 23.9 15.7–32.2
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3.2. Household Income
According to literature, the disease significantly impacts on the personal income,
because patients are frequently unable to work. International comparisons are very difficult
due to the heterogeneity of average income in UE countries. Looking at Eurostat [12],
the mean equivalized net income in 2018 was respectively €19,208 (Italy), €25,642 (UK),
and €8740 (Latvia). However, in Italy and the UK, only 44.1% and 54.6% respondents
respectively declared an income higher than €15,000, which supports the hypothesis of an
impact of the disease on individual productivity. In Latvia, no patients declared an income
higher than €15,000, but this is due to the fact that income is relatively lower in this country.
This international comparison is summarized in Table 2.
Table 2. Household incomes.
Item Country No. Respondents No. Responding‘Yes’ %
95% Confidence
Interval (%)
Household income (No. with > €15,000 p.a.) Italy 85 38 44.1 28.6–60.8
Household income, per member
(No. with > €15,000 p.a.)
Latvia 65 0 0.0 -
UK 443 242 54.6 48.2–61.0
3.3. Disease Progression and Management
There were significant differences between the three countries in the proportions
of respondents reporting having had more than ten investigations, having experienced
more than ten symptoms, or having had more than five treatments. Italian respondents
reported the most investigations and treatments and the most symptoms, which may be
associated with a lack of appropriates guidelines for diagnosing ME/CFS, and the Latvians
least, with the UK respondents occupying an intermediate position. UK respondents were
significantly more likely than others to report that their symptoms fluctuated in severity
(Table 3).
3.4. Perceived Effectiveness of Treatment
As regards the use of non-pharmacological treatments, in all three countries there
were free text responses concerning the treatments followed during the last five years, in
particular physiotherapy, cognitive behaviour therapy (CBT) and graded exercise therapy
(GET). For all countries, physiotherapy is the most widespread treatment, with 41.7%
Italian patients receiving it (or having received it in the last five years), 30.8% Latvian
patients and fewer UK patients (14.3%). CBT was also reported by 23.5% Italians, 33.3%
Latvians, and 7.0% UK participants.
A specific question asked if patients considered non-pharmacological treatments
effective. Whilst in Italy only 8% patients answered positively, this percentage rises at 52%
for Latvia and 57.7% for UK.
With regards to this item, it seems that Italian patients are not satisfied with the
therapies received. A specific response regarding GET was obtained only from the UK, and
it is noteworthy that only one respondent found it effective. These findings are detailed in
Table 4.
3.5. Responsibility for Medical Care
GPs were significantly more likely to have primary responsibility for medical care in
Latvia than in either Italy or the UK. This probably reflects the situation that there is not
a specific patients’ organization for ME/CFS in Latvia, and the GP is a ‘gate-keeper’ for
patients in diagnostic and treatment process. In Italy, the search for a correct diagnosis and
the absence of appropriate guidelines for the disease identification pushes patients to ask
for specialist consultations, as well as many diagnostic tests being performed before a final
diagnosis is arrived at.
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Table 3. Disease progression and management.






Italy 88 11.0 3.0 10.4–11.6
Latvia 75 7.5 2.5 6.9–8.1
UK 445 8.0 4.1 7.6–8.4
Treatments:
- All
Italy 88 0.5 0.2 0.33–0.67
Latvia 75 2.5 1.2 2.2–2.8
UK 425 3.0 3.0 2.7–3.3
- Drug treatment
Italy 88 0.5 0.2 0.33–0.67
Latvia 75 2.3 1.3 2.0–2.6
UK 425 1.3 4.0 0.9–1.7
- Non-drug treatment
Italy - - - -
Latvia 75 1.2 1.0 1.0–1.4
UK 425 1.7 2.1 1.5–1.9
No. investigations Italy 88 10.4 2.4 9.9–10.9
Latvia 75 5.7 3.2 5.0–6.4
UK 178 12.8 29.0 8.5–17.0
No. respondents reporting:
>10 investigations
Italy 88 65 73.9 63.0–84.8
Latvia 75 3 4.0 0.0–26.6
UK 178 86 48.3 37.5–59.1
>10 symptoms
Italy 88 64 72.7
Latvia 75 7 9.3 4.6–18.0
UK 445 86 19.3 1.8–27.8
>5 treatments
Italy 88 29 32.9 24.0–43.3
Latvia 75 0 0.0 -
UK 425 63 14.8 5.9–23.8
Variability of symptoms
Italy 86 48 55.8 41.5–70.1
Latvia 75 53 70.7 58.2–83.2
UK 446 410 91.9 89.2–94.6
On the contrary, specialists had little involvement in the care of the UK patients. Other
healthcare professionals were involved in the care of a higher proportion of UK respondents
than was found in either Italy or Latvia. In the latter case, there was very little involvement
of other professionals (see Table 5).
3.6. Personal Care
Significantly fewer Latvian respondents had family assistance with personal care than
was found in either Italy or the UK. Other (non-family) sources of personal care assistance
were reported by Italian or Latvian patients while nearly a fifth of UK respondents were
cared for by non-family members. No external help with personal care was reported by
nearly one in five of Italian respondents and a smaller proportion of UK ones. No response
from Latvian patients. A large proportion of Italian and Latvian respondents reported
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that they had capacity for self-care, as well as a significantly smaller proportion, but still a
majority, of UK respondents (Table 6).
Table 4. Perceived effectiveness of treatment.
Item Country No. Respondents No.Responding ‘Yes’ %
95% Confidence
Interval (%)
Treatments practiced in the last five years
Physiotherapy
Italy 84 35 41.7 31.7–52.9
Latvia 39 12 30.8 18.6–46.4
UK 28 4 14.3 0.0–49.3
Cognitive behaviour therapy (CBT)
Italy 85 20 23.5 15.8–34.2
Latvia 39 13 33.3 20.3 = 49.0
UK 115 8 7.0 0.0–24.9
Graded exercise therapy (GET)
Italy - - - -
Latvia - - - -




Italy 88 7 8.0 0.0–28.4
Latvia 75 39 52.0 36.0–68.0
UK 356 204 57.3 50.4–64.2
Table 5. Responsibility for medical care.
Item Country No. Respondents No. Responding ‘Yes’ % 95% ConfidenceInterval (%)
Responsibility for medical care:
- GPs
Italy 85 41 48.2 32.6–63.8
Latvia 75 57 76.0 64.7–87.3
UK 446 189 42.4 35.2–49.6
- Specialists
Italy 85 67 78.8 68.8–88.8
Latvia 75 44 58.7 43.8–75.5
UK 446 35 7.9 0.0–16.9
- Other
Italy 84 18 21.4 2.1–40.8
Latvia 75 5 6.7 0.0–29.0
UK 446 62 35.9 5.1–22.7
Table 6. Personal care.
Item Country No. Respondents No. Responding ‘Yes’ % 95% ConfidenceInterval (%)
Assistance with Personal Care:
- family
Italy 85 70 82.3 73.2–91.5
Latvia 72 17 23.6 11.0–24.9
UK 413 293 70.9 65.6–76.2
- others
Italy 85 1 1.2 0.0–22.7
Latvia 72 0 0.0 -
UK 413 76 18.4 9.5–27.3
- No-one
Italy 85 16 18.8 0.0–38.4
Latvia 72 0 0.0 -
UK 413 31 7.5 0.0–17.0
Capacity for self-care (number
responding ‘Yes’)
Italy 84 73 86.9 79.0–94.8
Latvia 72 58 77.3 70.2–90.9
UK 443 253 57.1 50.9–63.3
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3.7. Difficulty Explaining the Illness
One of the major difficulties for CFS/ME patients consists in explaining the symptoms.
In Italy and the UK, around three-quarters of all respondents reported difficulty explaining
their illnesses to physicians, but in Latvia only a quarter of respondents had this problem.
This difference was statistically significant. When it came to explaining the illness to the
family, though, nearly three-quarters of Italian respondents had trouble, while for Latvia
and UK this figure decreases to less than 50%. Again, this difference was statistically
significant. A quarter of Latvian respondents expressed difficulty explaining their illnesses
to friends, compared with about two-thirds of British respondents and more than four-
fifths of Italian ones. All these differences were statistically significant. The Latvians least
frequently had difficulty explaining their illnesses to employers, compared with more than
half of UK respondents and nearly two-thirds of Italians. However, these differences were
not statistically significant (Table 7).
Table 7. Difficulty explaining the illness.
Item Country No. Respondents No. Responding ‘Yes’ % 95% ConfidenceInterval (%)
Difficulty explaining illness to:
- Physicians
Italy 86 63 73.2 62.1–84.4
Latvia 75 20 26.7 18.0–37.6
UK 444 343 77.3 72.7–81.8
Family
Italy 84 60 71.4 59.8–83.1
Latvia 75 35 46.7 35.8–57.9
UK 446 222 49.8 43.1–56.5
Friends
Italy 83 68 81.9 72.6–91.3
Latvia 75 20 26.7 18.0–37.6
UK 444 290 65.3 59.7–70.9
Employers
Italy 76 49 64.5 50.8–78.1
Latvia 75 30 40.0 29.7–51.3
UK 407 233 57.2 50.8–63.7
3.8. Quality of Life
In all three countries, a marked diminution in quality of life (scored 0 to 100) between
the year before illness and the most recent year was reported. All these changes were
statistically significant. The reported quality of life prior to illness was significantly higher
in Italy than in the other countries and was lowest in Latvia. The diminution in perceived
life quality as a result of illness was lowest in Latvia, where the mean quality of life score
during illness was significantly higher than in either Italy or the UK. Indeed, it was in
Italy where the greatest decline in average quality of life as a result of illness occurred
(Table 8). To this extent, a study was carried out in Italy aimed at demonstrating the impact
of selected variables on the probability of experiencing a decrease higher than 50 points in
self-reported quality of life. It turned out, for example, that having more than 10 symptoms
and being treated with more than 5 treatments was associated with this large reduction in
quality of life [13].
Table 8. Quality of life.
Item Country No. Respondents Mean SD 95% ConfidenceInterval (%)
Quality of life:
- before illness Italy 84 90.3 9.7 88.2–92.4
Latvia 74 74.6 24.0 69.0–80.2
UK 439 80.9 23.0 78.7–82.7
- in past year Italy 84 34.6 20.8 30.1–39.1
Latvia 74 57.3 16.3 53.5–61.1
UK 440 31.5 19.8 29.6–33.1
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3.9. Results of the Additional GP Survey in Latvia on the Management of CFS
In Latvia, there were 91 valid responses to the GP survey, which included questions
on the criteria for making a diagnosis, laboratory examinations, referral to specialists
and methods of treatment. For making the diagnosis, the results showed that 13 respon-
ders (14%) used the Fukuda case definition. 61 responders (67%) used the ICD-10 code
R53 (malaise and fatigue), while 18 (20%) used code G93.3 (post viral fatigue syndrome).
5 respondents (5.5%) used ICD-10 code B94.8 (sequelae of other specified infectious and
parasitic diseases). The multiplicity of codes used to record diagnoses of ME/CFS con-
tributes to the problem of determining numbers of patients. Moreover, 70% of GPs reported
that patients had difficulty in describing their symptoms. All the participating GPs used
laboratory tests in the diagnostic process, some more than others, with 35 respondents
(38%) using more than ten different tests. 65 GP respondents (71%) referred patients for
specialist care and diagnostic support. Specialists referred to included neurologists (62%),
psychiatrists or psychotherapists (30%), and infectious disease or other specialists (13%).
70% of GP respondents indicated the presence of comorbidities in their ME/CFS patients.
GP management included medication, referral to physiotherapy, psychotherapy, osteopa-
thy, homeopathy and lifestyle adjustment, but 59% of respondents regarded the disease as
incurable. Improvements to the care of ME/CFS patients suggested by GP respondents
included the development of a specialists’ consortium, better information for patients,
public funding for psychotherapy consultations, additional training, and more time for
conversation with patients.
4. Discussion
In the UK, treating physicians were not identified and therefore could not be inter-
viewed. Similarly, in Italy recruitment was via a patients’ organization and did not involve
treating physicians. In Latvia, participant selection was based on ICD-10 diagnoses. This
was following advice from the country’s only secondary referral center for ME/CFS. The
diversity of recruitment methods in the three countries was probably a source of strength
rather than weakness, as the findings from the survey from the three countries revealed
some very similar problems and concerns, suggesting that patients’ experiences were
universal in nature, and not confined to any one country or health care system. It is in-
teresting that, despite differences in health care systems, diagnostic methods, recruitment
methods and survey media, there was a very considerable similarity in the experiences of
respondents in all three countries.
Respondents in all three countries were similar in terms of average age and had the
same preponderance of females. There were no significant differences in the proportions
of respondents who were married or living alone, or who had post-school educational
qualifications. In Latvia, the UK, and Italy, net household incomes were lower than the
national average, indicating the impact of illness on incomes in all countries. As regards
illness management and progression, there were significant differences between the three
countries. Italians reported more symptoms, more investigations and more treatments
than respondents from the other countries, and the Latvians the least. This may be due
to the absence of appropriate guidelines for the management of the disease in Italy. We
did not elicit any information on the nature of the investigations carried out, because the
purpose of this question was to obtain a measure of the extent to which doctors in the
three countries were taking seriously their patients’ illnesses and were actively working to
investigate them.
Symptom fluctuation was significantly more marked among the UK respondents than
among the others. It was noteworthy that graded exercise therapy, in the UK, was found
to be universally ineffective, and none of the Italians reported having had this therapy.
There were reported differences between the three countries in who had responsibility
for providing medical care, but these may reflect differences in the management of the
disease in each country. Thus, GPs more frequently had principal responsibility for medical
care in Latvia than in Italy or the UK and this probably reflects the fact that in Latvia
Medicina 2021, 57, 300 9 of 12
GPs perform the gate-keeper role for patients in the diagnostic and treatment process.
Healthcare professionals other than doctors were more frequently involved in clinical care
in the UK than in either Latvia or Italy, which is likely to be related to the pattern of delivery
of primary care in the UK via the National Health Service.
In terms of personal care also, differences in response between the three countries were
more likely to reflect differences in the way in which social care is delivered in the three
countries. Thus, non-family care assistance was almost entirely confined to the UK, where
capacity for self-care was less prevalent that in the other countries. Similarly, variations in
difficulty explaining the disease to physicians was least widespread in Latvia, but this may
be attributable to the fact that physicians there were centrally involved in the identification
of potential respondents. Other variations, e.g., in explaining the illness to family, friends
or employers, may reflect differences in society in the three countries. Italians were most
likely to have trouble in explaining the illness to families, while Latvians had the least
difficulty explaining the illness to friends or employers, which suggests that there may be
greater understanding of the illness in the general population than is the case in either Italy
or the UK.
While there were differences between the three countries in perceived quality of life
both before and during illness, the trend was similar in Italy, Latvia, and the UK, with
marked diminution in quality of life being reported in all three countries as a result of
illness. In Latvia, the smaller gap in quality of life as a result of illness could be explained
by a greater decrease in quality of life before diagnosis, with a subsequent smaller decrease
in quality of life after diagnosis and initiation of treatment. While we do not wish to
overinterpret these data, it is likely that the initial differences between the three countries
reported prior to illness, for example in income and educational attainments, may reflect
overall socioeconomic differences between them, while there is substantial convergence
between all three countries in patient experience once illness becomes established.
The strength of this study is that this is the first study of ME/CFS patients conducted
on a transnational, comparative basis in Europe. It demonstrates that the basic demographic
features of the illness, in terms for example of the average age of participants and the gender
distribution, are very similar in the three countries studied. Where the responses from the
three countries differ, this largely reflects socioeconomic differences between countries, or
differences in the way in which medical services are delivered. Although there was not a
single template for the recruitment of patients, we endeavored to ensure the comparability
of patients through the recruitment process. Thus, in Italy, only patients with a recognized
diagnosis of CFS/ME were selected. Similarly, in Latvia, from almost 300 respondents
to the on-line survey on CFS symptoms, only participants with ICD-10 diagnosis codes
G93.3, R53 and B94.8 were involved in data analysis for the purposes of this paper, while
in the UK patients with medically confirmed diagnoses of ME/CFS were self-selected via
an internet-based patient support group.
The finding that ME/CFS has a substantial impact on net household income is consis-
tent with the previous conclusion of the socioeconomics working group of EUROMENE
that the economic impact of ME/CFS is substantial [5]. The reports of household income
are worrying, given average 2018 incomes of €25,642 in the UK, €19,208 in Italy, and €8740
in Latvia [12]. International comparisons are very difficult due to the heterogeneity of
average incomes in European countries, In Italy, 44.1% of respondents declared an income
higher than €15,000, while the comparable proportion among UK respondents was 54.6%
of respondents compared with 92% of the UK general population in 2017–18 [14]. In
Latvia, annual incomes among the general population are lower than in Italy and the UK.
No Latvian respondents reported an annual income per household member in excess of
€15,000. Despite these differences between the three countries under consideration, the
pattern is consistent; in all three countries, the respondents tended to report net incomes per
household member which were substantially lower than those found among the general
population. This underlines the negative impact of having ME/CFS on individual pro-
ductivity and capacity to work and indicates that this impact is substantial. Our findings
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are consistent with other research demonstrating a very substantial impact of ME/CFS
on productivity costs. Thus, Reynolds et al. analyzed data from a surveillance study of
ME/CFS in Wichita, Kansas, and concluded that lost productivity due to ME/CFS was
substantial both in absolute terms and in comparison with other major illnesses [15], while
Collin et al. analyzed data from the UK CFS/ME National Outcomes Database, and con-
cluded that ME/CFS causes huge productivity costs amongst the small fraction of adults
with ME/CFS who access specialist services [16].
The paper did not address the relationship between severity and economic impacts,
the importance of which we emphasized in a previous paper [5]. It is likely, though,
that productivity costs were higher among the more severely ill patients, because being
housebound or bedbound, severely ill patients are generally unable to work at all. Health
care system costs are more complicated, because many severely ill patients receive no
support or help from the health care system at all, due to the failure of primary care
physicians to diagnose the illness. Such failure is widespread, with evidence that between
a third to a half of all GPs, over several decades and a variety of geographical locations,
expressing disbelief or failing to recognize ME/CFS as a genuine clinical entity [17,18].
This is consistent with the finding that a large proportion of respondents, particularly
in Italy and the UK, have difficulty explaining their illness to doctors, as reported by the
working group’s literature review of knowledge and understanding of ME/CFS among
GPs [17], which established that disbelief and lack of knowledge were widespread in
primary care, while our survey of perceptions of GP knowledge and understanding among
EUROMENE participants suggests that this problem exists throughout Europe [18].
This study initiative aimed to identify policy measures designed to alleviate the
burden of disease on patients and their families, and on governments, in particular by
reducing delays in diagnosis, and has enabled certain changes in the way in which services
are delivered to be identified. Thus, in Latvia, the survey was paralleled by a survey of
GPs, in which a number of improvements were suggested, including establishment of a
consortium of specialists, the creation and use of clinical algorithms and patient pathways,
better information for patients, reimbursement from public funds of psychotherapists’
consultation fees, additional training, and more time for patient consultations. Another
possible improvement recommended from Latvia was the establishment of a disease
register, which would facilitate disease management by GPs, the development of patient
pathways, and improved disease monitoring.
5. Conclusions
This comparative survey of ME/CFS patients in Italy, Latvia, and the UK has demon-
strated marked similarities between respondents in all three countries in terms of demo-
graphic features, the impact of the illness on household incomes and on quality of life,
and on difficulties experienced by respondents in discussing their illness with doctors.
There were differences in terms of patterns of medical care, the availability of social care,
and societal attitudes to ME/CFS. There is a need for internationally shared protocols for
the disease treatment and diagnosis. More empirical research is required in Europe on
ME/CFS patients’ needs in order to develop adequate care pathways.
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